Tricida, Inc. (TCDA)

$9.62

-0.39 (-3.90%)
Rating:
Recommendation:
-
Symbol TCDA
Price $9.62
Beta 0.915
Volume Avg. 0.55M
Market Cap 533.188M
Shares () -
52 Week Range 3.55-12.45
1y Target Est -
DCF Unlevered TCDA DCF ->
DCF Levered TCDA LDCF ->
ROE 1148.09% Strong Buy
ROA -108.85% Strong Sell
Operating Margin -
Debt / Equity -255.50% Sell
P/E -
P/B -6.15 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TCDA news


Dr. Gerrit Klaerner
Healthcare
Biotechnology
NASDAQ Global Select

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.